Roivant Sciences Ltd. (ROIV) insider trading

By person

21 insiders · 304 transactions

834×

Matthew Gline holds 834 times base salary in stock. $604.92M of shares against $725.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Gline last reported holding, valued at $36.31, the price Common Shares was last bought or sold at on the open market here, on 3 Nov 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Daniel Allen Gold

Director

—

$341.57M (36)

−$341.57M

22,654,981

3.14%

$822.60M

−82.9%

QVT Financial LP entity

Director by Deputization

—

$300.69M (32)

−$300.69M

13,689,166

1.90%

$497.05M

−88.6%

Keith S Manchester

Director

—

$258.62M (30)

−$258.62M

15,442,623

2.14%

$560.72M

−81.0%

SVF Investments (UK) Ltd entity

10% owner

—

$242.63M (3)

−$242.63M

73,031,667

10.11%

$2.65B

−26.5%

Eric Venker

President & Immunovant CEO

—

$229.37M (95) scheduled

−$229.37M

999,154

0.1383%

$36.28M

−28.1%

Vivek Ramaswamy

10% owner

—

$224.96M (17)

−$224.96M

47,011,612

6.51%

$1.71B

−21.5%

Sumitomo Chemical Co., Ltd. entity

10% owner

—

$130.00M (1)

−$130.00M

71,251,083

9.86%

$2.59B

−17.5%

Viking Global Investors LP entity

10% owner

—

$128.70M (4)

−$128.70M

12,884,307

1.78%

$467.83M

−50.2%

Viking Global Performance LLC entity

10% owner

—

$128.70M (4)

−$128.70M

12,884,307

1.78%

$467.83M

−50.2%

Mayukh Sukhatme

President & CIO

—

$124.75M (17) scheduled

−$124.75M

18,563,884

2.57%

$674.05M

+513.7%

Frank Torti

President and Vant Chair

—

$82.04M (3) scheduled

−$82.04M

13,495,893

1.87%

$490.04M

—

Matthew Gline

CEO

$49.96K (1)

$71.78M (16) scheduled

−$71.73M

16,549,136

2.29%

$600.90M

+884.1%

Dexcel Pharma Technologies Ltd. entity

10% owner

$20.15M (3)

—

+$20.15M

102,849,443

14.24%

$3.73B

+4.1%

Rakhi Kumar

Chief Accounting Officer

—

$9.87M (25) scheduled

−$9.87M

162,306

0.0225%

$5.89M

−38.8%

Richard Pulik

CFO

—

$9.14M (3) scheduled

−$9.14M

269,681

0.0373%

$9.79M

+15.2%

Meghan Fitzgerald

Director

—

$3.27M (5) scheduled

−$3.27M

41,162

0.0057%

$1.49M

—

Melissa B, Epperly

Director

—

$2.65M (7) scheduled

−$2.65M

15,351

0.0021%

$557.39K

—

Jennifer Humes

Chief Accounting Officer

—

$384.07K (1)

−$384.07K

106,419

0.0147%

$3.86M

+20,484%

Ilan Oren

Director

—

124,490

0.0172%

$4.52M

—

James C Momtazee

Director

—

112,265

0.0155%

$4.08M

—

Andrew Lo

Director

—

52,142

0.0072%

$1.89M

—

Roivant Sciences Ltd.

What the insiders did Net selling

By person